Day One: Opioid Summit

Tuesday, September 24

This educational programming is designed for physicians and healthcare professionals delivering opioid use disorder prevention, intervention, treatment and recovery services across the continuum of care.

Agenda

8:30 – 9 a.m.

Registration

Continental breakfast will be provided.

9 – 9:30 a.m.

Welcome & Introductions

  • Courtney Burke, Chief Operating and Innovation Officer, HANYS
  • Valerie White, Deputy Director, Surveillance, Prevention, Administration and Drug User Health, The AIDS Institute, New York State Department of Health

9:30 – 10:15 a.m.

Keynote Address

Collaborative Treatment, Cultural Shifts and Commitment to Health Equity

Dr. Waldman will present findings on evidence-based interventions for the treatment of OUD. She will also discuss the importance of social determinants in medical care and the role of incorporating these practices and principles within a harm reduction framework in order to address the epidemic as a whole. Dr. Waldman will address how the adoption of these practices and principles provide the cultural shift necessary to lower healthcare costs and avoid future epidemics involving populations that are often marginalized within the healthcare system.

Learning objectives

By the end of this session, participants will be able to:

  • explain why cultural shifts and attention to social determinants of health are needed to improve access to and quality of care for individuals with OUD;
  • outline evidence-based principles for medication-assisted treatment, harm reduction, recovery and support strategies for effective treatment of individuals with OUD;
  • explore collaborations with community-based organizations to improve the effectiveness of care across the continuum supporting recovery; and
  • describe how a harm reduction approach to the opioid epidemic will save money and significantly improve patient outcomes.

10:15 – 10:30 a.m.

Break

10:30 – 11:15 a.m.

Stigma Toward Substance Use in the Healthcare Setting

This session will help attendees understand the role of stigma toward substance use within healthcare settings as it relates to people with lived experience of drug use and guide them in developing strategies to combat harmful stigmatizing practices through compassion and evidence-based information.

Learning objectives

By the end of this session, participants will be able to:

  • explain the various health and social consequences of drug-related stigma;
  • describe effective anti-stigma campaigns and strategies to improve the health and rights of people who use drugs; and
  • discuss how healthcare providers can advocate against discriminative practices and policies.

11:15 a.m. – noon

The Cycle of Addiction: Opioid Use Disorder in Pregnancy and Primary Care

  • Paul Updike, MD, Medical Director of Substance Use Services, Catholic Health System

This session will increase participants’ understanding of addiction, explain how primary care and OB/GYN clinicians can intervene and integrate MAT services into their practice and review specific treatment issues associated with pregnancy and OUD.

Learning objectives

By the end of this session, participants will be able to:

  • develop an enhanced understanding of the pathophysiology of addiction;
  • discuss how buprenorphine prescribing can be incorporated into a primary care and obstetrics setting; and
  • describe the preferred treatment options associated with pregnancy, such as breastfeeding and pain management.

Noon – 1:45 p.m.

Working Lunch

12:45 – 1:45 p.m.

Treatment Without Walls: Cross Collaboration and Community Connections Along the Continuum of Care

Moderator:

  • Allan Clear, Director, Office of Drug User Health, NYSDOH AIDS Institute

Panelists:

In this session, panelists will provide an overview of MAT within the Buffalo Matters buprenorphine expansion program, New Choices Recovery Center’s Center of Treatment Innovation project, drug user Health Hubs and the Albany County Jail MAT program. Participants will increase their knowledge regarding treatment innovations, harm reduction, common barriers and collaborative efforts underway to support individuals and families battling OUD across the continuum of care.

Learning objectives

By the end of this session, participants will be able to:

  • discuss innovations in substance use disorder treatment in emergency department, community and jail-based settings;
  • identify common barriers experienced by those seeking SUD/OUD treatment;
  • describe areas of integration to support the full continuum of care; and
  • discover opportunities for further training and collaboration across systems.

1:45 – 2:45 p.m.

Harm Reduction Through Peer Engagement

This session will explore the process of recovery through the lens of persons with lived experience and help participants become more knowledgeable about harm reduction and peer engagement support.

Learning objectives

By the end of this session, participants will be able to:

  • discuss how peer support and harm reduction can influence positive outcomes in recovery;
  • explain the person-centered approach to engagement strategies for MAT in various settings; and
  • describe how support and collaboration with community partners is essential.

2:45 – 3 p.m.

Break

3 – 3:30 p.m.

Opioids, Hepatitis C and Invasive Infections

This session will explore the association between the opioid epidemic and the rise of hepatitis C and invasive infections.

Learning objectives

By the end of this session, participants will be able to:

  • review the burden of hepatitis C and invasive infections among people who inject drugs;
  • describe national and state-level hepatitis C and invasive infection trends; and
  • identify the role of healthcare facilities in reducing hepatitis C and invasive infections.

3:30 – 4:15 p.m.

Clinical and Pharmacological Evidence-based Treatment for MAT

This session will help attendees understand the principles and rationale for low threshold prescribing of buprenorphine.

Learning objectives

By the end of this session, participants will be able to:

  • discuss how to respond to continued use of opioids and other substances to discuss the utility/role of toxicology testing;
  • dispel the myths and misconceptions around MAT from clinical and non-clinical staff;
  • outline strategies to explain the role of counseling in OUD; and
  • describe the components of a short assessment and induction as well as ongoing follow-up visits.

4:15 – 4:30 p.m.

Closing Comments

  • Alan Wilmarth, CASAC, Administrative Director, Behavioral Health, United Health Services; Chair, HANYS Behavioral Health Task Force